Skip to content
- Can one Protocol govern several Study identities under a master-protocol design?
- Can different participant groups concurrently follow different approved Protocol Versions?
- Which protocol concepts must be executable rather than governed narrative?
- What makes a change a correction versus a Protocol Amendment?
- Is site activation one decision or a composed assessment plus explicit authorization?
- Can one Facility have multiple Study Sites in the same Study?
- Which responsibilities belong to Organizations, Persons, or both?
- How should investigator replacement affect delegation and signatures?
- What creates a new participant identity versus another screening episode?
- Can a participant have multiple concurrent participations under one master protocol?
- Which activities remain permitted after consent withdrawal?
- How does site transfer affect scheduled activities and responsibility?
- Is the Protocol schedule authoritative for every downstream product?
- When does one clinical activity produce several independent occurrences?
- How are conflicting source observations resolved without erasing either source?
- Which corrections require reopening prior review or decisions?
- Which actors and systems belong to each blind partition?
- What is the minimum safe cross-domain treatment-assignment fact?
- When does clinical data create a Safety Case versus only a Safety Intake?
- Which safety changes require updates to clinical data or analysis?
- Can clinical data scopes be locked independently?
- Who owns exceptions to each lock prerequisite?
- What evidence must remain usable after replacing a vendor or application?
- When does a document become a Trial Artifact, and when does an artifact satisfy an
Essential Record expectation?